Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Neximmune Inc (NEXI)

Neximmune Inc (NEXI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 324
  • Shares Outstanding, K 1,395
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,340 K
  • EBIT $ -21 M
  • EBITDA $ -20 M
  • 60-Month Beta 1.68
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.54
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -18.29
  • Most Recent Earnings $-1.69 on 08/07/24
  • Next Earnings Date 12/27/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2151 +7.86%
on 11/27/24
0.4100 -43.41%
on 11/27/24
-0.0080 (-3.33%)
since 11/20/24
3-Month
0.2000 +16.00%
on 10/01/24
0.4238 -45.26%
on 10/31/24
-0.0180 (-7.20%)
since 09/20/24
52-Week
0.2000 +16.00%
on 10/01/24
28.6949 -99.19%
on 01/30/24
-2.0280 (-89.73%)
since 12/20/23

Most Recent Stories

More News
Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders

Selexis SA , a JSR Life Sciences company, and NexImmune Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies, announced today that they have...

NEXI : 0.2320 (-14.77%)
NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers

First IND for NexImmune’s AIM nanoparticle platform in solid tumorsIND clearance enables commencement of a clinical trial to evaluate NEXI-003, an...

NEXI : 0.2320 (-14.77%)
Legend Capital Portfolio: Japan's NO.1 VTuber Operator ANYCOLOR Lists on the Tokyo Stock Exchange

HONG KONG, Jun 9, 2022 - (ACN Newswire) - On June 8th 2022, Legend Capital's portfolio company ANYCOLOR, a leading Virtual YouTuber (VTuber) management company in Japan, was listed on the Tokyo Stock Exchange....

NEXI : 0.2320 (-14.77%)
AXNX : 70.98 (+0.75%)
OMIC : 19.55 (-1.96%)
NexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates

Clinical data updates for the Company’s two lead product candidates in Phase 1/2 clinical trials expected in 2H2022Investigational New Drug (IND)...

NEXI : 0.2320 (-14.77%)
NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes

A JDRF funded grant will be used to explore the combination of NexImmune’s antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment...

NEXI : 0.2320 (-14.77%)
NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors

GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to...

NEXI : 0.2320 (-14.77%)
NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center’s Herbert Irving Comprehensive Cancer Center

GAITHERSBURG, Md., April 26, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach...

NEXI : 0.2320 (-14.77%)
NexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific Officer

Dr. Oelke is a scientific co-founder of NexImmune and a pioneer in the field of artificial antigen presenting cell (aAPC) technology...

NEXI : 0.2320 (-14.77%)
NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation

GAITHERSBURG, Md., March 17, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) and Zephyr AI (Zephyr) today announced a strategic partnership...

NEXI : 0.2320 (-14.77%)
NexImmune Announces Melanoma Research Collaboration with NYU Langone’s Perlmutter Cancer Center

GAITHERSBURG, MD, March 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach...

NEXI : 0.2320 (-14.77%)

Business Summary

NexImmune Inc. is a clinical-stage biotechnology company. It engages in developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent and durable immune response that mimics natural biology. NexImmune Inc. is based in GAITHERSBURG, Md.

See More

Key Turning Points

3rd Resistance Point 0.3038
2nd Resistance Point 0.2891
1st Resistance Point 0.2605
Last Price 0.2320
1st Support Level 0.2172
2nd Support Level 0.2025
3rd Support Level 0.1739

See More

52-Week High 28.6949
Fibonacci 61.8% 17.8098
Fibonacci 50% 14.4475
Fibonacci 38.2% 11.0851
Last Price 0.2320
52-Week Low 0.2000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar